Insulin-like Growth Factor I Receptor: A Novel Target for Hepatocellular Carcinoma Gene Therapy

Mini Rev Med Chem. 2019;19(4):272-280. doi: 10.2174/1389557518666181025151608.

Abstract

Human insulin-like growth factor (IGF) axis affects the molecular pathogenesis of hepatocellular carcinoma (HCC), especially in the abnormality of hepatic IGF-I receptor (IGF-IR) or IGF-II expression as a key molecule in hepatocarcinogenesis. However, the over-expression of hepatic IGFIR is associated with HCC progression with largely unknown mechanisms. The IGF-IR as one key molecule of the IGF signal pathway plays an important role in the hepatocyte malignant transformation. Attaching importance to IGF-IR might improve the prognostic or the therapeutic technique of HCC. This article reviews IGF-IR alteration during HCC development, and the effects of silencing IGF-IR gene by specific short hairpin RNA on the inhibition of cell proliferation in vitro or HCC xenograft growth in vivo to elucidate it as a novel molecular-targeted therapy for HCC.

Keywords: Hepatocellular carcinoma; cell proliferation; gene amplification; gene therapy; insulin-like growth factor-I receptor; molecular targeted; xenograft tumor..

Publication types

  • Review

MeSH terms

  • Carcinoma, Hepatocellular / genetics*
  • Carcinoma, Hepatocellular / therapy*
  • Gene Expression Regulation, Neoplastic / genetics
  • Genetic Therapy / methods*
  • Humans
  • Liver Neoplasms / genetics*
  • Liver Neoplasms / therapy*
  • Molecular Targeted Therapy
  • Receptor, IGF Type 1 / genetics*

Substances

  • Receptor, IGF Type 1